Table 3.
Therapeutic effects and demonstrated mechanisms of α-Bisabolol in skin disorders.
| Skin Disorders | ||||
|---|---|---|---|---|
| Compound | Dose/Route/ Duration |
Model | Major Mechanisms | Reference |
| α-Bisabolol | 1% topical spray | Randomized controlled trial on chronic venous leg ulcer patients | ↓ wound and ulcer surface area ↑ healing speed |
[37] |
| α-Bisabolol | 0.3 g/100 g cream twice daily for 8 weeks | Prospective, randomized, reference-controlled, double-blind, two-center and four-armed parallel group study on patients with atopic dermatitis | ↓ pruritis, inflammation ↑ healing |
[39] |
| α-Bisabolol | 1% cream once-daily for 30 days | Single-center, single-arm, prospective, open-label study on patients with melasma |
↓ melasma area and severity index (MASI) score ↑ patient satisfaction |
[40] |
Symbols indications: ↑; increase, ↓; decrease.